Emyria (EMD) H2 2026 earnings summary

Executive summary

• Expanded from one to five clinics across four major Australian states, with Sydney clinic opening soon and 18 operational beds.

• Achieved a 475% increase in patients treated year-over-year, reaching 138 cumulative patients.

• Trained clinician workforce grew from 30 to 145, and prescribers from 6 to 17, supporting rapid clinic expansion.

• Established key partnerships with Medibank and DVA, moving treatments into mainstream healthcare.

• Launched Empax Global Partnership Program, supporting international clinical trials and new revenue streams.

Financial highlights

• Revenue increased from AUD 1.3 million ($1.39M) in FY2025 to over AUD 4 million ($4.05M) in FY2026, with total income nearing AUD 4.3 million including R&D.

• Each dosing day generates approximately AUD 10,000 ($10,000) in revenue.

• Perth clinic reached break-even and profitability at the clinic level.

• Operational clinics increased from 1 to 5, and operational beds from 4 to 18 year-over-year.

• Number of clinicians trained rose from ~30 to ~145, and prescribers from 6 to 17.

Outlook and guidance

• Focus on increasing utilization of existing clinics and expanding the network through hospital partnerships.

• Exploring additional reimbursement pathways, including more private health and workers' compensation insurers.

• Plans to grow Empax Global Partnership Program and support more international drug sponsors.

• Actively considering expansion into new jurisdictions outside Australia, including New Zealand and the USA.